Ionis Pharmaceuticals, Inc. (IONS) CEO Stanley Crooke on Q2 2019 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q2: 2019-08-07 Earnings Summary

EPS of -$0.01 beats by $0.19
 | Revenue of $164.00M (39.28% Y/Y) beats by $18.69M

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2019 Earnings Conference Call August 7, 2019 11:30 AM ET

Company Participants

Wade Walke - VP, IR
Stanley Crooke - Chairman and CEO
Elizabeth Hougen - CFO
Brett Monia - COO
Damien McDevitt - Chief Business Officer

Conference Call Participants

Tyler Van Buren - Piper Jaffray
Jim Birchenough - Wells Fargo
Chad Messer - Needham & Company
Ritu Baral - Cowen & Company
Yale Jen - Laidlaw & Company
David Lebowitz - Morgan Stanley
Jessica Fye - JP Morgan

Operator

Good morning, and welcome to Ionis Pharmaceuticals Second Quarter 2019 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Vice President of Investor Relations, to lead off the call. Please begin.

Wade Walke

Thank you, Nicole. Before we begin, I encourage everyone to go to the Investor section of Ionis Web site to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our Web site that accompany our discussion today.

With me on the call are Stan Crow, Chairman of the Board and Chief Executive Officer; Beth Hougen, Chief Financial Officer; Brett Monia, Chief Operating Officer; and Damien McDevitt, Chief Business Officer, who will join us for Q&A.

I would like to draw your attention to slide three, which contains our forward-looking language statement. We'll be making forward-looking statements, which are based on current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for

Recommended For You

About IONS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on IONS